liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Level of TNF-related apoptosis-inducing-ligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers
Antalya Education and Research Hospital, Turkey.
Antalya Education and Research Hospital, Turkey.
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Onkologi. Linköpings universitet, Hälsouniversitetet.
German Cancer Research Centre, Heidelberg, Germany.
Vise andre og tillknytning
2013 (engelsk)Inngår i: Medical Science Monitor, ISSN 1234-1010, E-ISSN 1643-3750, Vol. 19, s. 875-882Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background

The changes and correlations of TRAIL (TNF-related apoptosis-inducing-ligand) and CXCL8 (IL8) prior to treatment and three months following therapy as well as the corresponding Positron emission tomography (PET/CT) (SUVmax: standardized uptake maximum values) results were evaluated.

Material/Methods

The measurements were taken before and after treatment for comparison purposes. The study population comprised 29 patients with Metastatic Colorectal cancer (MCRC), undergoing PET/CT scanning prior to treatment.

Results

There were significant changes prior to treatment and three months later for sTRAIL (p=0.0080) and CXCL8 (p=0.0001)values. Generally, sTRAIL values were increasing during therapy, while a decrease was observed for CXCL8. Correlation analysis was applied to the data and revealed significant correlations for the SUVmax in the primary tumor prior to treatment and CXCL8 prior to therapy (p=0.0303). Furthermore, significant correlations were observed for the SUVmax and sTRAIL (p=0.0237) as well as CXCL8 (p=0.0002) three months after treatment initiation. CXCL8 prior to treatment was also correlated with the SUV three months after onset of treatment (p=0.0072). A significant correlation was noted for one combination of two variables, the SUVmax in the metastases and CXCL8 prior to treatment (p=0.0175). These results are supported when we group the SUVmax in the metastases following treatment into two groups with SUVmax <5 and SUVmax >5.

Conclusions

This study provides evidence that proteomics patterns of sTRAIL and CXCL8 predict tumor response und survival in MCRC patients treated with bevacizumab and within a high concordance of FDG-PET/CT findings.

sted, utgiver, år, opplag, sider
Medical Science International , 2013. Vol. 19, s. 875-882
Emneord [en]
metastatic colorectal cancer (MCRC), CXCL8 (IL8), soluble TRAIL (sTRAIL), anti VEGF antibody (Bevacizumab), F-18-Deoxyglucose positron emission tomography (FDG-PET/CT), proteomics study, (SUVmax: standardized uptake maximum values)
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-100477DOI: 10.12659/MSM.889605ISI: 000325846300001PubMedID: 24145180OAI: oai:DiVA.org:liu-100477DiVA, id: diva2:662981
Tilgjengelig fra: 2013-11-08 Laget: 2013-11-08 Sist oppdatert: 2017-12-06bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Bisgin, Atil

Søk i DiVA

Av forfatter/redaktør
Bisgin, Atil
Av organisasjonen
I samme tidsskrift
Medical Science Monitor

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 32 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf